<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04992715</url>
  </required_header>
  <id_info>
    <org_study_id>PELICAN</org_study_id>
    <secondary_id>2020-002809-26</secondary_id>
    <nct_id>NCT04992715</nct_id>
  </id_info>
  <brief_title>PD-L1 Expression in Lung Cancer</brief_title>
  <acronym>PELICAN</acronym>
  <official_title>A Single-arm, Phase II Study to Evaluate PD-L1 Expression in Non-Small Cell Lung Cancer Using the 99mTc Labelled Anti-PD-L1 Single Domain Antibody (NM-01)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NanoMab Technology (UK) Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guy's and St Thomas' NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NanoMab Technology (UK) Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will measure PD-L1 expression in metastatic NSCLC (primary tumour and metastatic&#xD;
      lesions) using [99mTc]-NM-01 SPECT/CT and compare to PD-L1 percentage expression determined&#xD;
      by immunohistochemistry (IHC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A non-blinded, single centre, single interventional arm Phase II diagnostic imaging study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PD-L1 Expression Assessment using [99mTc]-NM-01 SPECT/CT</measure>
    <time_frame>Day 0</time_frame>
    <description>To measure PD-L1 expression in NSCLC (primary tumour and metastatic lesions) as assessed using [99mTc]-NM-01 SPECT/CT and compare to PD-L1 expression determined by IHC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of [99mTc]-NM-01 SPECT/CT assessed through incidence of Adverse Drug Reactions</measure>
    <time_frame>Up to 12 days post-injection</time_frame>
    <description>To assess the safety of [99mTc]-NM-01 SPECT/CT scan by observing for Adverse Drug Reactions (ADRs) occurring during the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD-L1 expression heterogeneity as assessed by [99mTc]-NM-01 SPECT/CT tumour to blood-pool ratios in each lesion</measure>
    <time_frame>Day 0</time_frame>
    <description>To measure intra-tumoural heterogeneity in the primary tumour, as well as in individual metastases and inter-tumoural heterogeneity between different disease sites (including different metastatic sites and between primary tumour and its metastases).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory Objectives</measure>
    <time_frame>Up to 16 weeks post-injection</time_frame>
    <description>To correlate the SPECT/CT PD-L1 assessment with other diagnostic parameters such as blood tumour mutation burden test and to detect the presence of anti-drug antibodies to [99mTc]-NM-01.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Metastatic Non-Small Cell Lung Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with metastatic non-small cell lung cancer will be recruited as per protocol inclusion/exclusion criteria and will undergo [99mTc]-anti-PDL1 single-domain antibody ([99mTc]-NM-01) SPECT/CT imaging.&#xD;
[99mTc]-NM-01 SPECT/CT images will be compared to immunohistochemistry PD-L1 expression results.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>[99mTc]-NM01 SPECT/CT</intervention_name>
    <description>Technetium-99m radiolabelled anti-PD-L1 single-domain antibody (NM01) single-photon emission computed tomography (SPECT)/computed tomography (CT)</description>
    <arm_group_label>Metastatic Non-Small Cell Lung Cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 or above&#xD;
&#xD;
          -  Patients with histopathology confirmed untreated metastatic NSCLC scheduled for&#xD;
             systemic anti-cancer therapy&#xD;
&#xD;
          -  ECOG status ≤ 1&#xD;
&#xD;
          -  Willingness and ability to comply with scheduled study visits and tests&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Concomitant uncontrolled medical conditions as per Investigator assessment&#xD;
&#xD;
          -  &gt; 3 months between IHC PD-L1 and study recruitment&#xD;
&#xD;
          -  Significant abnormality of haematology (one or more of: Hb ≤ 90g/L, absolute&#xD;
             neutrophil count (ANC) ≤1.5 x109/L, platelet count ≤75 x109/L)&#xD;
&#xD;
          -  Significant abnormality of renal function (defined as Cockcroft-Gault calculated&#xD;
             creatinine clearance ≤30 mL/min)&#xD;
&#xD;
          -  Significant abnormality of liver function (one or more of: AST or ALT ≥2.5x ULN or ≥&#xD;
             5x ULN if patient has liver metastases; total bilirubin ≥1.5xULN. In the case of&#xD;
             patients with Gilbert's syndrome then direct bilirubin must be confirmed as ≤ ULN)&#xD;
&#xD;
          -  Significant cardiovascular disease, including New York Heart Association (NYHA) heart&#xD;
             failure ≥Class III, myocardial infarction within 3 months of enrolment, unstable&#xD;
             arrhythmia or unstable angina&#xD;
&#xD;
          -  History of uncontrolled allergic reactions and/or have hypersensitivity to anti-PD-L1&#xD;
             monoclonal antibodies, kanamycin A or aminoglycoside therapies, or other excipients&#xD;
             that may induce hypersensitivity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary JR Cook</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guy's and St Thomas' NHS Foundation Trust | King's College London, London, UK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gary JR Cook</last_name>
    <phone>(0044)20 7188 7188 ext 88378</phone>
    <email>gary.cook@kcl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Honghoi Ting</last_name>
    <email>hhting@nano-mab.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Gary JR Cook</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Wong NC, Cai Y, Meszaros LK, Biersack HJ, Cook GJ, Ting HH, Mottaghy FM. Preclinical development and characterisation of (99m)Tc-NM-01 for SPECT/CT imaging of human PD-L1. Am J Nucl Med Mol Imaging. 2021 Jun 15;11(3):154-166. eCollection 2021.</citation>
    <PMID>34234994</PMID>
  </reference>
  <reference>
    <citation>Xing Y, Chand G, Liu C, Cook GJR, O'Doherty J, Zhao L, Wong NCL, Meszaros LK, Ting HH, Zhao J. Early Phase I Study of a (99m)Tc-Labeled Anti-Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non-Small Cell Lung Cancer. J Nucl Med. 2019 Sep;60(9):1213-1220. doi: 10.2967/jnumed.118.224170. Epub 2019 Feb 22.</citation>
    <PMID>30796165</PMID>
  </reference>
  <reference>
    <citation>Hughes DJ, Chand G, Goh V, Cook GJR. Inter- and intraobserver agreement of the quantitative assessment of [(99m)Tc]-labelled anti-programmed death-ligand 1 (PD-L1) SPECT/CT in non-small cell lung cancer. EJNMMI Res. 2020 Dec 1;10(1):145. doi: 10.1186/s13550-020-00734-x. Retraction in: EJNMMI Res. 2021 Oct 12;11(1):102.</citation>
    <PMID>33259032</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 19, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PD-L1 Expression</keyword>
  <keyword>Immunohistochemistry</keyword>
  <keyword>SPECT/CT Imaging</keyword>
  <keyword>Molecular Imaging</keyword>
  <keyword>Heterogeneity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

